Fig. 4From: Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment responseVEGF (top), HGF (middle) and angiopoietin-2 (bottom) levels per time point (baseline, +0, +1, +3, +7 and +30 days post treatment, respectively), for patients who had previously received bevacizumab (n = 25) and those who did not (n = 17)Back to article page